David Brennan, the chief executive of AstraZeneca, faces a vote for re-election to the board of the Anglo-Swedish pharmaceutical group at its annual general meeting on Thursday in the face of growing investor pressure for top-level change.
>via ft.com
No comments:
Post a Comment